Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
1-1-2022

Mean lifetime survival estimates following solid organ
transplantation in the US and UK
Christopher N Graham
Crystal Watson
Arie Barlev
Matt Stevenson
Vikas R Dharnidharka

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Journal of Medical Economics

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ijme20

Mean lifetime survival estimates following solid
organ transplantation in the US and UK
Christopher N. Graham, Crystal Watson, Arie Barlev, Matt Stevenson & Vikas
R. Dharnidharka
To cite this article: Christopher N. Graham, Crystal Watson, Arie Barlev, Matt Stevenson & Vikas
R. Dharnidharka (2022) Mean lifetime survival estimates following solid organ transplantation in the
US and UK, Journal of Medical Economics, 25:1, 230-237, DOI: 10.1080/13696998.2022.2033050
To link to this article: https://doi.org/10.1080/13696998.2022.2033050

© 2022 Atara Biotherapeutics. Published
by Informa UK Limited, trading as Taylor &
Francis Group.
View supplementary material

Published online: 11 Feb 2022.

Submit your article to this journal

Article views: 686

View related articles

View Crossmark data

Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ijme20

JOURNAL OF MEDICAL ECONOMICS
2022, VOL. 25, NO. 1, 230–237
https://doi.org/10.1080/13696998.2022.2033050
Article 0254-RT.R1/2033050

ORIGINAL RESEARCH

Mean lifetime survival estimates following solid organ transplantation in the US
and UK
Christopher N. Grahama
Vikas R. Dharnidharkad

, Crystal Watsonb

, Arie Barlevb

, Matt Stevensonc

and

a
Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA; bHealth Economics, Atara Biotherapeutics, South San Francisco,
CA, USA; cSchool of Health and Related Research, University of Sheffield, Sheffield, UK; dSt. Louis Children’s Hospital, Washington University
School of Medicine, St. Louis, MO, USA

ABSTRACT

ARTICLE HISTORY

Aims: Accurately estimating mean survival after solid organ transplant (SOT) is crucial for efficient
healthcare resource allocation decisions. However, registry-based post-transplant recipient survival estimates vary greatly and are incomplete. Often, the methods used in lifetime survival extrapolation may
not fit complex transplant data and therefore alternative methods are required. We aimed to explore
the flexible cubic spline methodology as a meaningful alternative for estimating lifetime survival following SOT.
Methods: Survival analyses were conducted in kidney, liver, heart, and lung transplant recipients.
Mean survival was estimated using flexible cubic splines on the hazard scale fitted with three knots,
based on where hazards changed direction, clinical advice, and best-fit curve using Akaike and
Bayesian information criterion. The tail was extrapolated when data were no longer available.
Extrapolation tails were compared with general population mortality, using age-matched life table hazards, and the highest hazards were taken at all times.
Results: We found that mean survival post-transplant was longest for kidney transplants (US:
22.79 years; UK: 26.58 years), followed by liver (US: 20.90 years; UK: 20.38 years), heart (US: 14.82 years;
UK: 15.85 years), and lung (US: 9.28 years; UK: 9.21 years). A sensitivity analysis using two knots found
differences in survival ranging from 1.30 to þ4.83 years across SOTs examined.
Limitations: This study does not represent individual patient survival, survival by age groups, multiple-organ transplants, or assess factors that may impact overall or organ survival.
Conclusions: Our study estimates reflect real-world survival following SOTs and demonstrate the
importance of including long-term hazards in survival estimations. These lifetime survival estimates
can be used by decision-makers in situations where means are preferred over medians (e.g. population
projections, budgetary estimates, and cost-effectiveness models) and can thus offer a meaningful alternative to the estimates used and accepted in current practice.
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Introduction
Organ transplantation has been available for over 60 years,
with the first successful solid organ transplant (SOT) conducted in 19541,2. SOT is now an established treatment
option for patients with end-organ damage3. In 2019,
approximately 153,863 SOTs were performed globally, the
most frequent being single kidney, liver, heart, and lung
transplants, accounting for over 95% of the transplant population4. The US and the UK have robust registries in place
that have been collating SOT data since the 1990s, i.e. the
Scientific Registry of Transplant Recipients (SRTR) and the UK
Transplant Registry (UKTR), respectively. The US has one of
the highest transplantation rates in the world, at 106.1 transplants per million population5. A total of 23,401 kidney,
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8,896 liver, 3,552 heart, and 2714 lung transplant recipients
received a graft in 2019, which comprises 98% of US transplants6. The US also has a high rate of pediatric transplants
(17 years of age), which account for 3–15% of the total SOT
population6. In contrast to the US, transplant rates in the UK
are lower (23.7 transplants per million population)7, largely
due to low donation consent among deceased donor families8. In 2019, a total of 3,601 kidney, 1,010 liver, 173 heart,
and 159 lung transplants were conducted in the UK, with up
to 9% of transplants conducted in the pediatric population7.
Through examination of SOT patient data, it has become
apparent that post-transplant recipient survival varies greatly
and is dependent on a number of variables such as SOT
type, transplant wait time, patient age and sex, and duration
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of hospitalization9–11. Over time, new therapies and transplant techniques have improved short-term survival outcomes; however, long-term survival of transplants has
stagnated12. Younger recipients exhibit markedly increased
survival over adults, with reported survival of 25 years, an
increase of more than 10 years compared with adults in
some SOTs12. Despite this, true lifetime survival of SOT recipients is unknown; even though registry follow-up can span
upwards of 20 years, most transplant recipients are alive at
the end of follow-up and lifetime survival estimates must
be used.
Estimating lifetime survival is crucial for economic models
that assist in planning for healthcare resource allocations
(e.g. budget impact analyses) or determining if an intervention is good value for money (e.g. cost-effectiveness analyses). Extrapolation methods utilizing parametric distributions
such as exponential, Weibull, and log logistic are frequently
used for survival analyses; however, different distributions
can result in significantly different survival estimates, particularly when a substantial amount of extrapolation is
required13,14. These simple parametric methods may not fit
complex data such as those from SOT patients, and therefore
other approaches such as cubic splines may be needed to
better extrapolate the data. Cubic splines join smoothed
mathematical functions together at points known as “knots”
to capture complex hazard and survival functions15,16. A
comprehensive review of survival extrapolation methods
reported that combining shorter-term, individual-level data
with longer-term, external data in flexible parametric modeling using cubic splines combines the advantages of many
extrapolation models and is more robust than several other
methods examined16,17. Furthermore, the UK National
Institute for Health and Care Excellence (NICE) Decision
Support Unit (DSU) guidance recommends utilizing both
patient-level and external data to minimize extrapolation and
confirm clinical plausibility of the extrapolation and any
changes in the underlying hazards13. By taking into account
the complex data in SOT populations and including longterm hazards in the survival extrapolations, this study sought
to explore the flexible cubic spline methodology as a meaningful alternative method for estimating mean lifetime survival in US and UK patients following the most prevalent
single SOTs (kidney, liver, heart, and lung).

Materials and methods
This study used data from the SRTR. The SRTR data system
includes data on all donor, wait-listed candidates, and transplant recipients in the US, submitted by the members of the
Organ Procurement and Transplantation Network (OPTN).
The Health Resources and Services Administration (HRSA), US
Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. The
SRTR includes detailed patient and graft survival data for all
SOTs in the US from 1990 to 2018. This study also used data
from the UKTR (held by the National Health Service [NHS]
Blood and Transplant), which includes patient and graft survival for all SOTs in the UK from 1995 to 2017.
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Separate survival analyses were conducted for the US and
UK using patient-level data for four single SOT types: kidney,
liver, heart, and lung. Variables extracted for this study
included age group at transplant, organ transplanted, time
to death, and censoring/event flag. Patient-level data and
registry variables were assessed for data inconsistencies, and
preliminary Kaplan–Meier survival and hazard rates analyzed
to aid in projection methods.
Following NICE DSU guidance on survival analyses13, traditional parametric survival analyses were first carried out
using six distributions: exponential, generalized gamma,
Gompertz, log logistic, log normal, and Weibull. Goodness-offit was assessed with fit statistics (Akaike information criterion [AIC] and Bayesian information criterion [BIC]) and overlays of fitted curves and Kaplan–Meier plots (see analysis
plan in Supplementary Figure S1). Owing to the complex
hazards of survival post-transplant, traditional parametric
models did not fit well, and analysis moved on to flexible
cubic spline models as recommended in the guidance13.
To minimize potential model overfitting, hazard rates
were plotted over time using the kernel density estimator in
the R muhaz package (Supplementary Figure S2) and a clinical expert identified time periods where hazard rates
changed direction for each organ type by country. Hazard
inflection points corresponded to clinically important periods
of time (e.g. short-term graft rejection, mid-term graft rejection, long-term survivors). Flexible cubic splines with hazard
scale were fitted with the identified two and three knots for
each organ within each dataset using R flexsurv package
(Table 1). Weibull distribution was used between each knot,
with flexible cubic splines providing the smoothing. The
Weibull distribution allowed hazard rates to go in one direction between knots and change direction and magnitude at
each knot. As the knots were manually placed at hazard
inflection points, scales that allowed frequent changes in direction between knots, such as normal and odds scales, were
not deemed appropriate. The Weibull hazard scale, which
allows only monotonic changes to the hazard between knots
and directional changes at knots/inflection points, was considered more in line with real-world survival.
The extrapolation tails were compared with general population mortality, using age-matched life table hazards based
on the US and UK life tables for the total population18,19. An
adjustment was applied in situations where cubic spline hazards were less than the general population hazards and survival curves (i.e. the highest hazard was taken at all times).
Goodness-of-fit statistics and graphical overlays of
Kapan–Meier plots and fitted curves were used to determine
the best-fit models. Survival was calculated as the area under
Table 1. Knot placements per solid organ transplant for the US and
UK analyses.
US
UK

Kidney (year)
Liver (year)
Lung (year)
Heart (year)

k¼1

k¼2

k¼3

k¼1

k¼2

k¼3

1
1
2
1

2
2
10
2

13
15
16
18

1
1
4
2

2
2
10
3

12
23
16
18

Abbreviation. k, knot.
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the curve for each fitted model for each organ within each
data set.
This study was conducted using existing databases of deidentified transplant recipients; therefore it did not require
institutional review board/independent ethics committee approval.

At the end of follow-up, the highest percentage of patients
at risk (patients still alive and in the registry) was in kidney
SOTs, with 3.1% of US patients and 3.9% of UK patients at
risk, whereas in lung SOTs this dropped to 0.3% of US
patients and 0.8% of UK patients.

Results

Mean lifetime survival estimates following SOT

Epidemiological data

After applying the parametric functions for extrapolation
(exponential, generalized gamma, Gompertz, log logistic, log
normal, and Weibull), none were considered a good fit and
fitting moved on to three-knot and two-knot models (Table
3). The hazard plots showed inflection points, leading to
splines being the preferred method for extrapolation.
Flexible cubic splines with hazard scales were applied and fitted with two and three knots that were identified with the
clinical expert (Table 1). Based on AIC/BIC analysis, the threeknot splines were the best-fit scales for all organ transplants
for the US, followed closely by the two-knot splines. Similar
results were seen in the UK with the three-knot splines being
the best-fit for kidney, liver, and heart followed by the twoknot splines. For lung transplants in the UK, which has the
lowest total number of transplants, the AIC/BIC for the threeknot and two-knot splines were similar and less than 15
points of the lowest AIC/BIC (generalized gamma). Based on
clinical advice and goodness-of-fit, the three-knot splines
were considered the base case for all transplants across both
countries and the two-knot splines were analyzed as a sensitivity analysis (Table 3). As described in the methods, the
hazard was not allowed to fall below that of the general
population18,19.

Survival data for 621,447 SOT recipients in the US and 60,919
SOT recipients in the UK were analyzed. This comprised
382,663 kidney, 137,579 liver, 64,868 heart, and 36,337 lung
transplants in the US and 40,133 kidney, 13,957 liver, 3,917
heart, and 2,912 lung transplants in the UK (Table 2 and
Figure 1). Adults represented the majority of transplants in
both countries, with kidney and liver transplants being the
most prevalent transplants captured in both the US and UK
populations. In both countries, over 60% of all SOTs were
conducted in the 31–60 age groups, with the lowest number
of transplants seen in the 70 age group. In the US, there
was a lower percentage of overall transplants conducted
between 1990 and 2004, with percentages increasing from
2005 onwards. In the UK, a similar low trend was observed
between 1995 and 2009, with an increase in overall transplant percentages from 2010 onwards, most prominently in
liver and lung transplants.

Patient-level survival data
Kaplan–Meier survival curves were plotted based on 28 years
of US patient data and 22 years of UK patient data (Figure 1).

Table 2. Patient baseline characteristics and transplant year category.a
All
Kidney transplants
Liver transplants
US
Age group (n, %)
<18
38,755 (6)
18–30
57,189 (9)
31–50
206,153 (33)
51–60
174,004 (28)
61
145,346 (23)
Transplant year category (n, %)a
1990–1994
75,390 (12)
1995–1999
89,516 (14)
2000–2004
105,738 (17)
2005–2009
118,301 (19)
2010–2014
120,764 (19)
2015–2018
113,640 (18)
Total
621,447
UK
Age group (n, %)
<18
5,180 (9)
18–30
7,044 (12)
31–50
21,767 (36)
51–60
15,801 (26)
61
11,126 (18)
Transplant year category (n, %)a
1995–1999
11,604 (19)
2000–2004
11,593 (19)
2005–2009
13,059 (21)
2010–2014
17,176 (28)
2015–2016
7,487 (12)
Total
60,918
a

Heart transplants

Lung transplants

16,952 (4)
43,752 (11)
143,061 (37)
93,943 (25)
84,955 (22)

12,449 (9)
5,828 (4)
39,342 (29)
47,909 (35)
32,051 (23)

8,383 (13)
4,345 (7)
15,960 (25)
20,672 (32)
15,508 (24)

971 (3)
3,264 (9)
7,790 (21)
11,480 (32)
12,832 (35)

48,347 (13)
55,407 (15)
66,600 (17)
73,543 (19)
72,841 (19)
66,086 (17)
382,663

13,777 (10)
18,789 (14)
23,887 (17)
27,507 (20)
27,826 (20)
26,979 (19)
137,579

10,820 (17)
11,164 (17)
10,159 (16)
10,213 (16)
11,352 (17)
11,557 (18)
64,868

2,446 (7)
4,156 (11)
5,092 (14)
7,038 (19)
8,745 (24)
9,018 (25)
36,337

2,550 (6)
5,129 (13)
15,473 (39)
9,160 (23)
7,820 (20)

1,813 (13)
1,055 (8)
4,219 (30)
4,240 (30)
2,630 (19)

685 (18)
408 (10)
1,212 (31)
1,299 (33)
313 (8)

132 (5)
452 (16)
863 (30)
1,102 (38)
363 (13)

6,984 (17)
7,215 (18)
8,911 (22)
11,894 (30)
5,129 (13)
40,132

2,834 (20)
3,025 (22)
2,850 (20)
3,637 (26)
1,611 (12)
13,957

1,300 (33)
811 (21)
662 (17)
755 (19)
389 (10)
3917

486 (17)
542 (19)
636 (22)
890 (31)
358 (12)
2,912

US patient-level data were recorded from 1990 to 2018, while UK patient-level data were recorded from 1995 to 2017.
Abbreviation. n, number of patients.
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Figure 1. Comparison of Kaplan–Meier plots of patient survival following SOT in the US and UK. Number at risk represents the number of registry patients still
alive at each time point. Abbreviation. SOT, solid organ transplant.

Table 3. Fit statistics for all parametric and knot functions applied to the US and UK data.a
US
Function
Kidney
k¼3
k¼2
Exponential
Generalized
Log logistic
Log normal
Weibull
Liver
k¼3
k¼2
Exponential
Generalized
Log logistic
Log normal
Weibull
Lung
k¼3
k¼2
Exponential
Generalized
Log logistic
Log normal
Weibull
Heart
k¼3
k¼2
Exponential
Generalized
Log logistic
Log normal
Weibull

UK

AIC

BIC

AIC rank

BIC rank

AIC

BIC

AIC rank

BIC rank

gamma

2,763,376
2,765,451
2,772,840
2,769,761
2,777,715
2,804,791
2,771,672

2,763,430
2,765,494
2,772,851
2,769,794
2,777,737
2,804,813
2,771,693

1
2
5
3
6
7
4

1
2
5
3
6
7
4

169,897
169,899
170,822
170,499
171,181
172,725
170,813

169,940
169,933
170,830
170,525
171,198
172,742
170,830

1
2
5
3
6
7
4

2
1
4
3
6
7
5

gamma

1,043,435
1,043,689
1,062,790
1,045,150
1,050,995
1,056,018
1,047,619

1,043,484
1,043,728
1,062,800
1,045,180
1,051,015
1,056,038
1,047,639

1
2
7
3
5
6
4

1
2
7
3
5
6
4

83,890
83,935
86,754
84,453
84,981
85,339
84,714

83,928
83,965
86,762
84,476
84,996
85,354
84,729

1
2
7
3
5
6
4

1
2
7
3
5
6
4

gamma

380,010
380,100
382,660
380,125
383,107
385,587
380,778

380,053
380,134
382,668
380,150
383,124
385,604
380,795

1
2
5
3
6
7
4

1
2
5
3
6
7
4

30,608
30,611
31,192
30,606
30,874
30,972
30,697

30,637
30,635
31,198
30,624
30,886
30,984
30,709

2
3
7
1
5
6
4

3
2
7
1
5
6
4

gamma

603,846
604,028
616,671
607,292
616,159
621,395
611,410

603,891
604,065
616,680
607,319
616,177
621,413
611,428

1
2
6
3
5
7
4

1
2
6
3
5
7
4

33,986
34,001
35,957
34,404
34,837
34,966
34,626

34,017
34,026
35,963
34,422
34,849
34,979
34,639

1
2
7
3
5
6
4

1
2
7
3
5
6
4

a
Gompertz function did not converge for any SOT type, therefore the fit statistics are not available.
Abbreviations. AIC, Akaike information criterion; BIC, Bayesian information criterion; k, knot.

Mean estimated survival using the three-knot spline and
life tables was longest following kidney transplant, at 22.79
years in US recipients and 26.58 years in UK recipients
(Table 4 and Figure 2(a,b)). This was followed by liver transplants, with a mean estimated survival of 20.90 years in the
US and 20.38 years in the UK (Table 4 and Figure 2(c,d)),
while heart transplants had mean survivals of 14.82 years in

the US and 15.85 years in the UK (Table 4 and Figure 2(g,h)).
In both countries, mean estimated survival was lowest in
lung transplant recipients: 9.28 years in the US and 9.21 in
the UK (Table 4 and Figure 2(e,f)).
To investigate how knot placement affected the survival
estimates, a sensitivity analysis was conducted using a twoknot fit that assumed there were no differences in hazard

234

C. N. GRAHAM ET AL.

Table 4. Mean estimated lifetime survival post-transplant.
Organ
Base-case analysis
Sensitivity analysis
(k ¼ 3 and LT)
(k ¼ 2)
US
Kidney
Liver
Lung
Heart
UK
Kidney
Liver
Lung
Heart

Difference

22.79
20.90
9.28
14.82

21.49
24.04
8.52
15.57

1.30
þ3.14
0.76
þ0.75

26.58
20.38
9.21
15.85

28.15
25.21
8.57
17.60

þ1.57
þ4.83
0.64
þ1.75

Abbreviations. k, knot; LT, life table.

direction over the long-term. The sensitivity analysis showed
small differences in mean survival across all SOTs, the differences ranging from 1.30 years to þ3.14 years in the US and
0.64 to þ4.83 years in the UK (Table 4). The differences in
mean estimated survival were lowest in lung and heart transplants in the US (0.76 years and þ0.75 in the sensitivity
analysis vs base-case survival, respectively; Figure 2(e,g)), and
in lung transplants in the UK (0.64 years vs base-case survival, Figure 2(f)). The SOTs most affected by long-term hazards and exhibiting the largest differences in mean
estimated survival were liver transplants in the US
(þ3.14 years vs the base case, respectively; Figure 2(c)), and
liver transplants in the UK (þ4.83 years vs the base case,
Figure 2(d)).
Survival estimates without life table adjustments are provided in Supplementary Figure S3. Removing the life table
adjustment on mean estimated survival for liver (US:
21.80 years; UK: 20.42 years), heart (US: 14.82 years; UK:
15.85 years) and lung transplants (US: 9.43 years; UK:
9.23 years) had minimal to no impact (range ¼ 0–0.90 years)
due to the older mean ages at transplant and shorter survival after transplants. Since kidney transplant recipients are
younger, with the ability to go on dialysis if the graft fails,
removing the life table adjustments (US: 24.07 years; UK:
27.37 years) impacted the estimates by 0.79–1.28 years.

Discussion
The methodology and extrapolation reported in this study
estimated the mean survival for SOTs by organ type and
country, utilizing registry data from the US and UK. Since
simple parametric models were not a good fit, flexible cubic
splines and hazard scales were used to calculate survival estimates. Many SOT recipients had substantial mean lifetime
survival after transplant. The longest mean overall survival
was seen in kidney transplants, with 23 years in the US and
27 years in the UK. In both countries, the shortest mean
survival estimates were in lung transplants, with 9 years
after SOT.
Small differences in mean overall survival were seen
between the UK and the US. The largest country difference
was seen in kidney survival, where UK transplant recipients
were estimated to survive an additional 3.79 years compared
with US recipients. These country-specific differences are
likely related to the characteristics of the transplant

recipients; in the UK, a large proportion of the SOT population was under 30 years of age at the time of the SOT, while
in the US there was a disproportionate amount of patients in
the >60 age group (where outcomes may be less positive
than other age groups and survival will be shorter). Quality
of organs transplanted may be an impacting factor on survival estimates as well. The percentage of kidney transplants
from deceased donors are similar between the two countries
(72%)7,20; however, other patient-specific quality factors
(younger age, less time on dialysis and immunosuppression
regimen) can increase kidney transplant survival, which may
explain the observed increase in the UK.
The knot positions in the base-case analysis were agreed
on by a clinical expert, based on where hazards changed direction and opinion of whether changes were clinically appropriate or artifacts of the hazard estimation; this may result in
slight differences between the base case knot locations and
initial changes in direction of the hazard plots. The clinical
expert identified three time periods as clinically important
periods in SOT survival: short-term, mid-term, and long-term
survival. To examine the importance of long-term changes in
the hazards, we conducted a sensitivity analysis using only
the first two knots and assumed that there was no change in
the underlying distributions from mid- to long-term survival.
Overall, the sensitivity analysis showed small differences in
mean estimated survival in lung and heart transplants across
both countries; however, larger differences were observed in
US and UK liver transplants, with UK liver transplants exhibiting the largest difference, a near 5-year increase in survival
compared with the base-case analysis. Despite the increased
survival seen in some SOTs, the three-knot scale represents a
more conservative estimate of SOT survival compared with
the two-knot estimate, as it accounts for changes in survival
in the long-term and not just the short-term. The change in
the underlying distribution is particularly noticeable in liver
and kidney SOTs, where there is a higher percentage of
patients still alive at the end of follow-up.
Both the base-case and sensitivity analyses mean survival
estimates reported here are substantially higher than the
median lifetime survivals reported in previous literature, since
mean survival estimates allow for the inclusion of the tail
end distributions and outlier patients that are not accounted
for with medians. In a recent registry study, median survival
following kidney transplantation in the US and UK was
reported as 11.2 and 14.7 years, respectively21. Another US
registry study reported median liver and heart transplant survivals of 11.6 and 9.5 years, respectively22. An international
registry from 2019 reported that adult lung transplant
median survival was 4.8 years, while the survival of pediatric
recipients was 5.7 years, reflecting the low survival of these
recipients in the present study23,24. Thus, the difference
between the base-case-extrapolated mean survival in this
study and the reported median survival from registries
ranges from an additional 4–12 years, depending on the
type of SOT. Recently, the United States Renal Data System
(USRDS) registry estimated the expected remaining lifetime
of pediatric and young adult end-stage renal disease patients
using a conditional piecewise exponential survival and a
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Figure 2. Comparison of Kaplan–Meier plots of survival following SOT in the base-case (knot ¼ 3 and life tables) and sensitivity analysis (knot ¼ 2). (a) Kidney
transplant survival in the US; (b) kidney transplant survival in the UK; (c) liver transplant survival in the US; (d) liver transplant survival in the UK; (e) lung transplant
survival in the US; (f) lung transplant survival in the UK; (g) heart transplant survival in the US; (h) heart transplant survival in the UK. Abbreviations: K, knot; LT, life
table; SOT, solid organ transplant.

constant death rate within each age group. The expected
remaining lifetime ranged from 57.7 years in the 0–4 age
group to 42.3 years for the 18–21 age group, which are
closer to the mean lifetime survival reported in this study

when adjusting for age (22.79 years in the US and 26.58 years
in the UK for kidney)25,26. Other estimates exist in the literature, such as the SRTR annual data reports (ADRs) for SOTs,
which report on the percentage survival up to 5-years
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post-transplant20,27–29. These are valuable estimates for monitoring graft survival and quality; however, they do not capture the survival of the graft recipient over their lifetime.
Graft survival can be low in the first years following transplant, due to reasons such as graft rejection, type of donor,
quality of organ, etc, but that is not always representative of
recipient survival, especially long-term. Therefore, it is
important to examine lifetime survival to understand the full
impact of organ transplant on an SOT recipient. Since the
current study used all available SRTR data sets, the SRTR
ADRs can be used in tandem with this study to give a
greater understanding of short-term and lifetime transplant
survival, which is particularly useful in complex transplant
populations where survival may be influenced by a range
of factors.
The mean lifetime SOT survivals estimated in our study
are likely to be closer to the real lifetime survival of SOT
recipients than the survival estimates from registry data. Our
analysis fitted to available data and extrapolated end of life
based on hazard rates. In contrast, lifetime survival in the literature is frequently extrapolated based on the deaths that
occur within registries, which in SOT populations disproportionately represent older transplant recipients, and may not
be representative of the entire population. Lifetime survival
analyses often focus on estimating median survival, which is
unsuitable for populations with frequent outliers, such as the
SOT population. Estimating lifetime survival in this way also
results in the estimate being based on patients who received
transplants up to 20 years ago, without reflecting current
clinical practice or adjustments to reflect improvements in
survival over time30. For these reasons, mean lifetime survival
estimates may be preferred over medians when looking at
overall populations, as they are more representative of the
broader transplant population.
This study has certain limitations. The data used spanned
from 1990 to 2018, to minimize extrapolation and provide
the most mature data possible – the registry datasets used
contained 20–25 years of follow-up vs up to 5–10 years survival follow-up in more typical reports of registry datasets.
Consequently, changes in transplant techniques and
immunosuppression over time may cause survival to be
underestimated in this study. This study was based on the
full transplant recipient population and does not provide
results on an individual patient basis; while some patients
may be outliers and live longer, some may die quickly,
depending on a variety of factors. The analysis was conducted on the aggregate population and did not examine
the differences in survival between age groups – younger
patients may have better survival outcomes compared with
older patients. Multiple-organ transplants were excluded in
this analysis and therefore our survival estimates are only
applicable to those who have received single SOTs. The
examined registry data and survival analysis do not assess
factors that may impact lifetime survival, e.g. information on
treatments the patients received (including immunosuppression), patients’ comorbidities, diseases following transplant,
changes in treatments, time on the waiting list, etc. As these
data were not reported in the registries, our analysis was not

able to factor in any impact they may have on lifetime survival estimates: further studies are needed to examine these
factors and understand the key drivers influencing lifetime
survival estimates. In addition, the present analysis did not
include the life of the transplanted organ into the survival
estimations; therefore, survival may be underestimated in
certain SOT populations and overestimated in others.
In conclusion, the mean overall survival estimates in this
study are reported by the most common SOT organ type
(kidney, liver, heart, and lung) and for the US and UK. The
estimates in this study show substantially higher mean lifetime survival of kidney, liver, heart, and lung recipients compared with those previously reported in registries. The
methods used in this analysis serve as a valuable alternative
to those used in current practice for extrapolating lifetime
survival in SOT patients. The lifetime survival projections following SOT estimated by this analysis can be used as alternatives by decision-makers in situations where means are
preferred over medians (e.g. population projections, budgetary estimates, and cost-effectiveness models).
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